clinical trial · NCT07524348
A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
Samsung Bioepis Co., Ltd.·phase1·recruiting·n = 149
Advanced Solid TumorsE303
brief summary
This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors
started
Mar 23, 2026
primary completion
Jul 1, 2030
completion
Jul 1, 2030
last updated
Jun 1, 2026
official title
A Phase I, Open-Label, Multi-Center, First-in-Human Trial to Investigate E303, in Participants With Advanced Refractory Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol